share_log

川宁生物(301301.SZ):研发投入主要在合成生物学板块

Crown Bio (301301.SZ): Research and development investment mainly in the synthetic biology Sector.

Gelonghui Finance ·  Dec 16, 2024 08:37

On December 16, Gelonghui reported that Chuan Ning Biological (301301.SZ) stated on the investor interaction platform that the company's research and development expenses in the first three quarters of 2024 amounted to 44.0661 million yuan, an increase of 12.82% year-on-year, with a continuous growth in R&D expenses. The main reason for the relatively low proportion of total revenue is that the company's revenue is growing rapidly; the company's R&D investment is mainly in the synthetic biology Sector, which has a relatively high overall R&D input-output ratio.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment

    Statement

    This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.